Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuro-1
- Development stage
- Preclinical
- Lead developer
- Interdict Bio
- Modality
- Small Molecules
01
Overview
Neuro-1 is an early-stage small molecule drug candidate being developed by Interdict Bio for the treatment of neurodegenerative conditions, specifically Huntington's disease and Spinocerebellar ataxia (SCA). The program utilizes Interdict Bio's proprietary discovery platform to target the Huntingtin (HTT) protein and proteins associated with Spinocerebellar ataxia, which are central to the pathogenesis of these polyglutamine expansion disorders. Currently in the hit-to-lead phase of development, Neuro-1 aims to provide a therapeutic intervention by modulating these disease-driving proteins. Interdict Bio has indicated that it is seeking strategic partnerships to advance the Neuro-1 program through clinical trials.
02
Targets
HTT (Huntingtin protein)ATXN1 (Ataxin-1)
Beyond the preview
Go deeper on Neuro-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuro-1.